0001209191-23-054910.txt : 20231109
0001209191-23-054910.hdr.sgml : 20231109
20231109203509
ACCESSION NUMBER: 0001209191-23-054910
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231107
FILED AS OF DATE: 20231109
DATE AS OF CHANGE: 20231109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCormac Paul
CENTRAL INDEX KEY: 0001994981
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41855
FILM NUMBER: 231394341
MAIL ADDRESS:
STREET 1: C/O LEXEO THERAPEUTICS, INC.
STREET 2: 345 PARK AVENUE SOUTH, 6TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lexeo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001907108
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 854012572
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: FLOOR 6
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: (212) 547-9879
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: FLOOR 6
CITY: NEW YORK
STATE: NY
ZIP: 10010
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-07
0
0001907108
Lexeo Therapeutics, Inc.
LXEO
0001994981
McCormac Paul
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6
NEW YORK
NY
10010
0
1
0
0
Chief Technical Officer
0
Common Stock
2023-11-07
4
C
0
3191
A
17349
D
Series B convertible preferred stock
2023-11-07
4
C
0
29061
D
Common Stock
3191
0
D
Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
/s/ Jenny Robertson, Attorney-in-Fact
2023-11-09